EOS imaging, the pioneer in orthopedic 2D/3D imaging, has announced that the U.S. FDA has cleared the Micro Dose feature for pediatric imaging.
EOS’ continued advancement of low dose radiation imaging addresses an important medical need for pediatric patients that remain particularly sensitive to adverse effects associated with excessive exposure to radiation. Notable examples include pediatric patients with orthopedic conditions such as scoliosis, who require frequent imaging sessions to monitor treatment progression. Repeated exposure to radiation can increase the risk of cancer later in life. The EOS Micro Dose feature represents an important imaging option and a breakthrough for these patients.
Initial results have been presented at the 2013 French Society of Radiology Annual Meeting (JFR 2013) and during the 2014 Annual Meeting of the Radiological Society of North America (RSNA 2014). Findings concluded that Micro Dose generates dosage levels equivalent to a week of naturally-occurring background radiation in pediatric patients receiving 2D and 3D follow-up examinations.
Marie Meynadier, CEO of EOS imaging, said, “The reduction of radiation exposure during orthopedic imaging exams remains a foremost concern among radiologists, orthopedic surgeons and patients. The Micro Dose solution is a giant step forward and is in full accordance with the ALARA (As Low As Reasonably Achievable) principle. We are pleased that the FDA’s clearance of our Micro Dose feature will now enable young patients to benefit from this technology in the United States.”
Source: Business Wire